Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
4SC Ag
4SC Reports on a Successful Financial Year 2007
April 13th, 2008
4SC AG (Frankfurt, Prime Standard: VSC) reports on the financial result of the financial year 2007. Revenues during the reporting period amounted to 1.376 million Euros and fell short 62.4 per cent of the revenues achieved for the same period in 2006 (3.664 million Euros). In the previous year, the "Drug Discovery and Development" segment alone contributed almost half of overall revenues with 1.683 million Euros as a result of the successful sale of the world-wide exclusive rights to the QSB substances. In 2007 4SC AG did not conclude any new licensing agreements, but focussed on increasing the value of its pipeline projects, above all its lead project for treating rheumatoid arthritis. As...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
|
Advertisement |
|
|
|
